Alzheimer's polypill shows promise in early trial
Disease control
Completed
This Phase 2 study tested a once-daily combination pill (polypill) in 121 adults aged 50–85 with very mild to severe Alzheimer's disease. Over 180 days, researchers measured changes in thinking, memory, and daily function using standard dementia scales. The goal was to estimate w…
Phase: PHASE2 • Sponsor: Noah Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC